银华国证港股通创新药ETF(159567) |
净值:
1.7865
|
日增长率:
-0.03%
|
累计净值:1.7865 | 2025-07-22 |
|
股票代码 | 股票简称 | 持股数量(股) | 持股市值(元) | 占基金净值比(%) |
01801 | 信达生物 | 3,632,000.00 | 259,676,668.16 | 9.52 |
02269 | 药明生物 | 11,036,000.00 | 258,148,787.13 | 9.47 |
06160 | 百济神州 | 1,766,900.00 | 238,153,754.45 | 8.73 |
09926 | 康方生物 | 2,478,000.00 | 207,789,722.60 | 7.62 |
01177 | 中国生物制药 | 40,766,000.00 | 195,548,672.46 | 7.17 |
01093 | 石药集团 | 24,638,000.00 | 173,008,405.57 | 6.34 |
01530 | 三生制药 | 7,376,500.00 | 159,093,530.49 | 5.83 |
03692 | 翰森制药 | 4,560,000.00 | 123,715,137.00 | 4.54 |
09688 | 再鼎医药 | 3,120,100.00 | 78,105,549.10 | 2.86 |
06855 | 亚盛医药-B | 978,500.00 | 68,264,245.24 | 2.50 |
报告期 | 股票占净比(%) | 债券占净比(%) | 现金占净比(%) | 净资产(元) |
2025-06-30 | 95.89 | - | 12.57 | 2,727,378,357.86 |
2025-03-31 | 95.31 | - | 26.83 | 701,682,258.72 |
2024-12-31 | 97.25 | - | 4.44 | 377,801,891.58 |
2024-09-30 | 91.61 | - | 22.63 | 205,752,133.89 |
2024-06-30 | 95.71 | - | 4.77 | 134,857,371.54 |